ebm medical tirzepatide The standard 2.5 mg starting dose of may be too high for some people. Some clinicians use lower customized doses in sensitive patients to reduce nausea, fatigue and excessive appetite suppression Tirzepatide (Mounjaro) for the Treatment

Survodutide, an investigational once-weekly GLP-1/glucagon receptor dual agonist, is showing a new direction in obesity care: fat-loss quality

Assessment, prescription, and delivery all 100% online from the comfort of your home, serving patients across Texas

Its primary approved indication in the United States is the reduction of excess abdominal fat in HIV-positive adults with lipodystrophy, a condition characterised by abnormal fat redistribution often associated with antiretroviral therapy

Clinical trials have reported average weight reductions of approximately 3 to 5 kilograms with shorter acting agents, while higher dose, longer acting formulations have produced more substantial losses exceeding 10 kilograms in some patient populations